icon-folder.gif   Conference Reports for NATAP  
 
  53rd ICAAC Interscience Conference on
Antimicrobial Agents and Chemotherapy
September 10-13, 2013, Denver CO
Back grey_arrow_rt.gif
 
 
 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Na´ve HIV Patients
 
 
  Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 10-13, 2013Denver, CO, USA
 
D Wohl1, C Cohen2, JE Gallant3, A Mills4, P Sax5, E DeJesus6, A Zolopa7, HC Liu8, K White8, MS Rhee8, J Szwarcberg8 1University of North Carolina, Chapel Hill, NC, US; 2Community Research Initiative of New England, Boston, MA, US; 3Southwest CARE Center, Santa Fe, NM, US; 4Anthony Mills MD, Inc., Los Angeles, CA, US; 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 6Orlando Immunology Center, Orlando, FL, US; 7Stanford University, Palo Alto, CA, US; 8Gilead Sciences, Foster City, CA, US

ICAAC1.gif

ICAAC2.gif

ICAAC3.gif

ICAAC4.gif

ICAAC5.gif

ICAAC6.gif

ICAAC7.gif

ICAAC8.gif

ICAAC9.gif

ICAAC10.gif

ICAAC11.gif

ICAAC12.gif

ICAAC13.gif

ICAAC14.gif

ICAAC15.gif